IQVIA (NYSE:IQV) Earns "Hold (C)" Rating from Weiss Ratings

Key Points

• IQVIA's stock has been restated with a "hold (c)" rating by Weiss Ratings, while several brokerages have issued buy ratings, with price targets up to $225.00.
• The company reported earnings of $2.81 per share for the last quarter, exceeding analysts’ expectations, with a revenue of $4.02 billion.
• Insiders have recently sold shares of IQVIA, decreasing their ownership, while institutional investors hold a significant 89.62% of the company's stock.

IQVIA (NYSE:IQV - Get Free Report)'s stock had its "hold (c)" rating restated by research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

A number of other brokerages have also commented on IQV. UBS Group boosted their price objective on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Redburn Partners set a $214.00 price objective on shares of IQVIA in a research report on Wednesday, September 3rd. Cowen reissued a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Jefferies Financial Group raised shares of IQVIA from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $195.00 to $225.00 in a research report on Tuesday, September 9th. Finally, William Blair reissued an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Eighteen research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and an average target price of $233.05.

IQVIA Stock Performance

Shares of IQV opened at $200.60 on Wednesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA has a twelve month low of $134.65 and a twelve month high of $237.34. The firm's 50 day moving average price is $188.35 and its two-hundred day moving average price is $168.04. The firm has a market cap of $34.10 billion, a P/E ratio of 29.03, a PEG ratio of 2.21 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business's revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, analysts forecast that IQVIA will post 10.84 EPS for the current fiscal year.

Insider Activity

In other news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider directly owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On IQVIA

Hedge funds have recently bought and sold shares of the business. Clal Insurance Enterprises Holdings Ltd increased its position in IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after acquiring an additional 131 shares during the period. Golden State Wealth Management LLC increased its position in IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after acquiring an additional 130 shares during the period. AllSquare Wealth Management LLC bought a new position in IQVIA during the first quarter worth about $33,000. Asset Dedication LLC grew its stake in IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company's stock worth $38,000 after buying an additional 168 shares in the last quarter. Finally, Trust Co. of Toledo NA OH acquired a new stake in IQVIA during the second quarter worth about $39,000. 89.62% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.